Tarsus Pharmaceuticals (TARS)
(Real Time Quote from BATS)
$70.46 USD
+0.32 (0.46%)
Updated Oct 13, 2025 03:23 PM ET
4-Sell of 5 4
D Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TARS 70.46 +0.32(0.46%)
Will TARS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARS
Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?
Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last?
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Other News for TARS
Slingshot Bullish appears for TARS after 0.34% move
TARS makes New 52 Week Closing High on October 9
Tarsus Pharmaceuticals price target raised to $85 from $80 at BofA
Tarsus Pharmaceuticals price target raised by $5 at BofA, here's why
New 52 Week Closing High appears for TARS after 1.94% move